Date: 29th November, 2025

To,
The Corporate Relationship Department
The Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Dear Sir/Madam,

Subject: Appointment of Statutory Auditor:
Ref: Regulation 30 of SEBI (LODR) Regulations, 2015

This is to inform you that the meeting of the Board of Directors of the Company was held today on 29th November 2025 at 7.00 pm. The Board of Directors considered and approved the unaudited financial results for the quarter and half year ended on 30th September 2025. The Meeting was concluded at 8.45 pm.

We herewith attach the profit and loss account for the quarter and half year ended on 30th September 2025 along with Assets Liabilities Statement and cash Flow Statement for the said period.

Kindly take the same on record.

With regards

For, Sarda Proteins Limited

Savaliya Khilan Hareshbhai
Digitally signed by Savaliya Khilan Hareshbhai
Date: 2025.11.29 21:59:51 +05'30'

Khilan Savaliya
Director
DIN: 08790209

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of Sarda Proteins Limited for the Half Year ended September 30, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Sarda Proteins Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sarda Proteins Limited (the "Company") for the half year ended September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian

Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, A H Mandaliya & Associates
CHARTERED ACCOUNTANTS
FRN: 146705W

HIREN JITENDRABHAI MANDALIYA
Digitally signed by HIREN JITENDRABHAI MANDALIYA
Date: 2025.11.29 21:55:24 +05'30'

(Hiren J. Mandaliya)
Partner
Mem. No. :- 140193
UDIN :- 25140193BMHTKU6261

Date :- 29.11.2025
Place :- Ahmedabad

SARDA PROTEINS LTD

CIN: L15142RJ1991PLC006353

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)

EMail: sardaproteins@yahoo.com, **website:** www.sardaproteins.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

Rs.in Lakhs

	Particulars	**Quarter Ended on**			**Half Year ended on**	**Half Year ended on**	**Year Ended**
		30.09.2025	**30.06.2025**	**30.09.2024**	**30.09.2025**	**30.09.2024**	**31.03.2025**
		Un-Audited	**Un-Audited**	**Un-Audited**	**Un-Audited**	**Un-Audited**	**Audited**
I.	Revenue from operations	430.38	1,095.46	14.00	1,525.84	14.00	2,419.10
II.	Other Income	10.54	0.08	-	10.62	-	0.06
III.	**Total Revenue (I+II)**	**440.92**	**1,095.54**	**14.00**	**1,536.46**	**14.00**	**2,419.17**
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-		-
	Purchase of Stock -in- Trade	387.12	1,128.54	-	1,515.66	-	2,391.07
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-	-
	Employee Benefit Expenses	0.75	0.75	1.10	1.50	5.30	8.94
	Finance Cost	-	-	-	-	-	-
	Depreciation and Amoritsation Expenses	-	-	-	-	-	-
	Other expenses	12.59	15.59	2.40	28.18	6.20	17.15
	Total Expenses (IV)	**400.45**	**1,144.88**	**3.50**	**1,545.33**	**11.50**	**2,417.15**
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	40.46	(49.34)	10.50	(8.88)	2.50	2.02
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	**40.46**	**(49.34)**	**10.50**	**(8.88)**	**2.50**	**2.02**
VIII.	Extraordinary Items	-	-	-	-	-	-
IX.	Profit/(Loss) before Tax (V-VI)	**40.46**	**(49.34)**	**10.50**	**(8.88)**	**2.50**	**2.02**
X.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	(1.51)
XI.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	**40.46**	**(49.34)**	**10.50**	**(8.88)**	**2.50**	**0.51**
XII.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XIII.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XIV.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XV.	Profit/(Loss) for the period (IX+XII)	**40.46**	**(49.34)**	**10.50**	**(8.88)**	**2.50**	**0.51**
XVI.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XVII.	**Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)**	**40.46**	**(49.34)**	**10.50**	**(8.88)**	**2.50**	**0.51**
	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59	172.59	172.59
XVIII	Earnings per Equity Share						
	(1) Basic	2.34	(2.86)	0.61	(0.51)	0.14	0.03
	(2) Diluted	2.34	(2.86)	0.61	(0.51)	0.14	0.03

On behalf of the Board
Sarda Proteins Ltd

Savaliya Khilan Hareshbhai

Digitally signed by Savaliya Khilan Hareshbhai
Date: 2025.11.29 22:01:11 +05'30'

Khilan Savaliya
Director
DIN: 08790209

SARDA PROTEINS LTD			
CIN: L15142RJ1991PLC006353			
Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)			
EMail: sardaproteins@yahoo.com, **website:** www.sardaproteins.com			
ASSETS LIABILITY STATEMENT AS ON 30TH SEPTEMBER, 2025			
			(Amount in Lakhs)
Sr. No.	Particulars	As at 30.09.2025 (In Rs.)	As at 31.03.2025 (In Rs.)
		(Un-Audited)	(Audited)
I.	ASSETS		
1	Non-current assets	12.98	12.04
	Total Non-Current Asset	12.98	12.04
2	Current assets		
	(a) Current investments	-	-
	(b) Financial Asset	-	-
	(i) Investment	-	-
	(ii) Trade Receivable	1,216.55	-
	(iii) Cash and Cash equivalent	13.21	3.38
	(iv) Bank Balance other than (iii) above	-	-
	(v) Loan	124.48	115.00
	(vi) Others (Advances)	7,342.73	134.38
	(c) Current Tax Assets (Net)		-
	(d) Other Current Asset	2.59	-
	Total Current Asset	8,699.56	252.76
	TOTAL ASSET	8,712.54	264.80
II.	EQUITY AND LIABILITIES		
A	Equity		
	(a) Share Capital	250.45	250.45
	(b) Reserves and Surplus	(21.53)	(12.65)
	Total Equity	228.92	237.80
B	Liabilities		
1	Non-Current Liabilities		
	(a) Financial Liabilities	15.50	2.50
	(i) Borrowings	15.50	2.50
	(c) Deferred tax liabilities / Asset	-	-
	(d) Othe Non-Current Liabilities	-	0.46
	Total Non-Current Liabilities	15.50	2.96
2	Current Liabilities		
	(a) Financial liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	218.65	22.41
	(A) total outstanding dues of micro enterprises and small enterprises		

	(B) total outstanding dues of Creditors other than micro enterprises and small enterprises		
	(b) Other Current Liabilities	8,248.75	1.63
	(c) Provisions	0.72	-
	(d) Current Tax Liabilities (Net)	-	-
	Total Current Liabilities	8,468.12	24.04
	TOTAL EQUITY AND LIABILITIES	8,712.54	264.80

Notes :-

1 The above results were approved by Audit Committee and by Board of Directors in their meeting held on 29.11.2025

2 The above stated results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standards and notified under Compaines (Indian Accounting Standards) Rules, 2015 (as amended), specified under Section 133 of Companies Act, 2013 and other

3 Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.

4 Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Cell Products".

5 No Investor Complaints were received during the quarter ended 30-Sep-2025 nor any pending as on 01-Oct-2025.

6 Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period and to make them comparable.

On behalf of the Board
Sarda Proteins Ltd

Savaliya Khilan Hareshbhai
Digitally signed by Savaliya Khilan Hareshbhai
Date: 2025.11.29 22:01:59 +05'30'

Khilan Savaliya
Director
DIN: 08790209

SARDA PROTEINS LTD		
CIN: L15142RJ1991PLC006353		
Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)		
EMail: sardaproteins@yahoo.com, **website:** www.sardaproteins.com		
STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2025		
		(Rs. In Lakhs)
Particulars	**Half Year Ended on 30.09.2025**	**Year Ended on 31.03.2025**
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	(8.88)	2.02
Adjustments for:		
Depreciation and amortisation expenses	-	-
Finance costs	-	(0.06)
Gratuity provision	-	-
Kasar vatav	-	-
Rent income	-	-
Dividend income	-	-
Interest income	(10.53)	
Interest on income-tax refund	-	-
Excess income-tax provision written back		-
Excess provision for gratuity written back		-
Surplus / loss on sale of property, plant and equipment	-	0.01
Operating profit before working capital changes	**(19.41)**	**1.97**
Adjustments for:		
Increase / (decrease) in trade and other receivables	(8,435.31)	(31.34)
Increase / (decrease) in inventories	-	-
Increase/(decrease) in trade payables, other liabilities and provisio	195.33	18.32
Cash generated from operations	**(8,259.39)**	**(11.05)**
Taxes paid	-	-
Cash flow before extraordinary items	(8,259.39)	(11.05)
Extraordinary items	-	-
Net cash flow from / (used in) operating activities	**(8,259.39)**	**(11.05)**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale of property, plant and equipment	-	-
Purchase of property, plant and equipment	-	-
Purchase of investments	-	-
Interest income	-	0.06
Dividend income	-	-
Net cash used in investing activities	-	0.06
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of share capital	-	-
Dividend paid (including dividend distribution tax)	-	-
Proceeds/repayment of pending share application money	8,248.75	-
Proceeds from long-term borrowings	9.94	2.50
Proceeds from short-term borrowings (net)	-	-
Interest & other borrowing costs	-	-
Interest received from others	10.53	-
Net cash used in financing activities	8,269.22	2.50
NET INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	9.83	(8.49)
Cash and cash equivalents as at beginning (Opening balance)	3.38	11.87
Cash and cash equivalents as at end of the year (Closing balance)	13.21	3.38
Net increase/ decrease	**9.83**	**(8.49)**

On behalf of the Board
Sarda Proteins Ltd

Savaliya Khilan Hareshbhai

Digitally signed by Savaliya Khilan Hareshbhai
Date: 2025.11.29 22:02:46 +05'30'

Khilan Savaliya
Director
DIN: 08790209